Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 596 • 2015 ACR/ARHP Annual Meeting
Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis
Letty G.A. Versteeg¹, Laura M.M. Steunebrink¹, Ina H. Kuper¹, Peter M. ten Klooster², Arie E. van der Bijl³, Harald E. Vonkeman⁴ and Mart A.F.J. van de Laar¹, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Pcgr, University of Twente, Enschede, Netherlands, ³Isala Klinieken, Zwolle, Netherlands, ⁴Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: Treat-to-target (T2T) in early Rheumatoid Arthritis (RA) has been successfully implemented in daily clinical practice. Patients achieve remission very early and during a follow-up…
Abstract Number: 2648 • 2015 ACR/ARHP Annual Meeting
Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy
Vappu Rantalaiho¹, Marjatta Leirisalo-Repo², Hannu Kautiainen³, Petri Mankinen⁴, Janne Martikainen⁵ and Kari Puolakka⁶, ¹Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ²Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Pharmacoeconomics & Outcomes Research Unit (PHORU), School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁵Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁶Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: To evaluate vitality, reduced paid and unpaid work ability, and productivity losses for patients with early rheumatoid arthritis (RA) available for work force at…
Abstract Number: 468 • 2015 ACR/ARHP Annual Meeting
Clinical and Ultrasonographic Inflammation in DMARD-Naïve Early Rheumatoid Arthritis (RA) – Impact of the 2010 ACR/EULAR Classification Criteria Versus the 1987 ACR Classification Criteria
Maria K. Jonsson^1,2,3, Siri Lillegraven², Lena B. Nordberg², Anna-Birgitte Aga², Hilde B. Hammer⁴, Inge C Olsen², Bjørg-Tilde Fevang^1,5, Tore K. Kvien², Espen A. Haavardsholm² and the ARCTIC Study Group, ¹Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Clinical Science, University of Bergen, Bergen, Norway, ⁴Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: ACR and EULAR published new classification criteria for RA in 2010, aiming for early identification of patients at risk of developing persistent and erosive…
Abstract Number: 609 • 2015 ACR/ARHP Annual Meeting
A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort
Jason Lee¹, VP Bykerk², George Dresser³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, J Carter Thorne², Diane Tin⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰ and CATCH Investigators, ¹Rheumatology, Western University, St. Joseph's Hospital, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Clinical Pharmacology and Toxicology, Western University, London, ON, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Institut de Rhumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: The mechanism of methotrexate in rheumatoid arthritis (RA) is complex. It may increase adenosine levels by blocking conversion to of xanthine to uric acid…
Abstract Number: 2655 • 2015 ACR/ARHP Annual Meeting
Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare
VP Bykerk^1,2, Clifton O. Bingham III³, Ernest H. Choy⁴, Daming Lin², Rieke Alten⁵, Robin Christensen⁶, Daniel E. Furst⁷, Francis Guillemin⁸, Sarah Hewlett⁹, Amye L. Leong¹⁰, Lyn March¹¹, Thasia Woodworth¹², Gilles Boire¹³, Carol Hitchon¹⁴, Shahin Jamal¹⁵, Edward C. Keystone¹⁶, Janet E. Pope¹⁷, J Carter Thorne¹⁸, Diane Tin¹⁹, Susan J. Bartlett^20,21,22 and CATCH Investigators and OMERACT Flare Group, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁵Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁶The Parker instutute, RC, Copenhagen, Denmark, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Lorraine, Nancy, France, ⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹⁰Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹²Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ¹³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁷Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ²⁰Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: A reference point for clinically important worsening (CIW) of RA disease activity requiring retreatment or escalation is needed for randomized trials of treatment withdrawal.…
Abstract Number: 470 • 2015 ACR/ARHP Annual Meeting
Disease Outcome in Patients Fulfilling the 2010 Classification Criteria for Rheumatoid Arthritis: The Impact of the Different Criteria Components
Ellen Sauar Norli^1,2, Gina Hetland Brinkmann^2,3, Tore K. Kvien², Olav Bjørneboe¹, Anne Julsrud Haugen³, Halvor Nygaard⁴, Cathrine Thunem⁵, Elisabeth Lie² and Maria Dahl Mjaavatten², ¹Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, ⁴Dept. of Rheumatology, Lillehammer Hospital of Rheumatic Diseases, Lillehammer, Norway, ⁵Dept. of Rheumatology, Betanien Hospital, Skien, Norway
Background/Purpose: The 2010 ACR/EULAR classification criteria for rheumatoid arthritis (2010 RA criteria) facilitate early classification of rheumatoid arthritis (RA). The criteria yield a score ranging…
Abstract Number: 611 • 2015 ACR/ARHP Annual Meeting
The Rapid Kinetics of Optimal Treatment with Subcutaneous Methotrexate in Early Inflammatory Arthritis
Anna O'Connor¹, J Carter Thorne², Diane Tin³ and Janet E. Pope⁴, ¹Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: Methotrexate (MTX) is standard treatment in RA. Absorption is better in subcutaneous MTX (scMTX), which may impact speed of onset. In RA, earlier time…
Abstract Number: 2678 • 2015 ACR/ARHP Annual Meeting
Vitamin D Serum Level in Early Arthritis Patients: Association with Disease Activity, Disability and Severity in the Espoir Cohort
Etienne Gamon¹, Gaël Mouterde², Cédric Lukas³, Mattea Orsini⁴, Raphaèle Seror⁵ and Bernard Combe⁶, ¹Immunologie Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Rheumatology Department, Hopital Lapeyronie, Montpellier, France, ³Hopital Lapeyronie, Montpellier, France, ⁴Epidemiology Unit, Hopital Lapeyronie, Montpellier, France, ⁵Rheumatology, AP-HP Bicêtre Hospital / Paris-Sud University, Le Kremlin-Bicêtre, France, ⁶Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Environmental factors may play a crucial role in auto-immune diseases. Besides tobacco, other factors like vitamin D are suspected to impact the onset and…
Abstract Number: 481 • 2015 ACR/ARHP Annual Meeting
Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis – Single Center Experience
Rok Ješe¹, Aleš Ambrožič¹, Natasa Gaspersic², Alojzija Hocevar¹, Boris Lestan¹, Martina Plešivčnik Novljan², Sonja Praprotnik¹, Ziga Rotar¹, Alenka Šipek Dolničar¹ and Matija Tomšič¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Background/Purpose: In early rheumatoid arthritis (RA), initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset is associated with a significant benefit in…
Abstract Number: 619 • 2015 ACR/ARHP Annual Meeting
Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Maria de Hair, Nicole IJff, Johannes Jacobs and Jacob van Laar, Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
On behalf of the Society for Rheumatology Research Utrecht (SRU) Background/Purpose: To investigate the frequency of long-term adverse events (AEs) in early rheumatoid arthritis (RA)…
Abstract Number: 2684 • 2015 ACR/ARHP Annual Meeting
Association Between Anxiety and Depression and Rheumatoid Arthritis Outcome: Results from an Inception Early Rheumatoid Arthritis Cohort
Sizheng Zhao^1,2, Samantha Hider³, Christopher Sparks², Faith Matcham⁴, James Galloway⁵, Cristina Estrach¹ and Nicola Goodson^1,2, ¹Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ²Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ³Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁴Psychological Medicine Clinical Academic Group, King's College London, London, United Kingdom, ⁵Academic Department of Rheumatology, King´s College London, London, United Kingdom
Background/Purpose: Anxiety and depression (A&D) are important comorbid conditions that affect patients with rheumatoid arthritis (RA). It is not known whether they impact on disease…
Abstract Number: 487 • 2015 ACR/ARHP Annual Meeting
Early Rheumatoid Arthritis Patients in the Worse Disease Trajectory Group Fail to Achieve Improvement in Physical Function
Cheryl Barnabe¹, Ye Sun², Susan J. Bartlett^3,4, Gilles Boire⁵, Carol Hitchon⁶, Edward C. Keystone⁷, Boulos Haraoui⁸, J Carter Thorne², Diane Tin⁹, Janet E. Pope¹⁰, VP Bykerk¹¹ and CATCH Investigators, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Institut de Rhumatologie, Montreal, QC, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Disease trajectories in early rheumatoid arthritis (ERA) are characterized by differences in absolute levels of disease activity and rates of improvement, with patients in…
Abstract Number: 968 • 2015 ACR/ARHP Annual Meeting
Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study
Michael Weinblatt¹, Clifton Bingham², Gerd Burmester³, VP Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Daljit Tatla⁸, Catherine Arendt⁹, Irina Mountian¹⁰, Brenda VanLunen¹¹ and Paul Emery¹², ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁷University Hospital, Maastricht, Netherlands, ⁸8010 Arco Corporate Dr, UCB Pharma, Raleigh, NC, ⁹Global Medical Affairs, UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Early stages of rheumatoid arthritis (RA) may provide a therapeutic window in which biologic agents are most effective.1 C-EARLY (NCT01519791) is a phase 3…
Abstract Number: 2689 • 2015 ACR/ARHP Annual Meeting
Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity Are Multifactorial in Early Rheumatoid Arthritis
Cécile Gaujoux-Viala¹, Nathalie Rincheval², Laure Gossec³, Francis Guillemin⁴, Maxime Dougados⁵, Jean-Pierre Daures⁶ and BG Combe⁷, ¹Nîmes University Hospital, Rheumatology Department; EA 2415, Montpellier University, Nîmes, France, ²Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, ³Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁴University of Lorraine, Nancy, France, ⁵Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France, ⁶Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, ⁷Lapeyronie, Montpellier, France
Background/Purpose: Patients and physicians often differ in their perceptions of rheumatoid arthritis (RA) disease activity, as quantified by the patient's global assessment (PGA) and by…
Abstract Number: 489 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Toxicity of Methotrexate Monotherapy in Daily Clinical Practice. Results from an Early Arthritis Clinic
Christian A. Waimann^1,2, Margarita Landi³, Fernando Dal Pra³, Gustavo Citera⁴, Maria Celeste Orozco⁴, Osvaldo Luis Cerda³, Federico Ceccatto⁵, Sergio Paira⁵, Francisco Colombres⁶, Alberto Berman⁷, Horacio Berman⁷, Anastasia Secco⁸, Marta Mamani⁸, Maritza Manzano⁸, Maria Victoria Martire⁸, Francisco Caeiro⁹, Maria Haye Salinas¹⁰, Alejandro J. Alvarellos¹⁰, Ana C. Alvarez¹⁰, Javier Rosa¹¹, Valeria Scaglioni¹², Enrique R. Soriano¹¹, Josefina Marcos¹³, Mercedes Argentina García¹⁴, AC Costi¹⁵, Alejandro Martinez¹⁶, Oscar Luis Rillo¹⁶, Edson Veloso¹⁷, Ricardo V. Juárez¹⁸, Maria Elena Crespo¹⁹, Ana Quinteros²⁰, Doralia Vasquez²⁰, C Ledesma²¹, Gabriela Salvatierra²¹, R Quintana²², Monica Sacnun²³ and Marcelo Abdala²⁴, ¹Rheumatology, Hospital Dr. Hector Cura, Olavarria, Argentina, ²Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁶Tucuman, Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁸Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁰Rheumatology, Hospital Privado de Córdoba, Córdoba, Argentina, ¹¹Hospital Italiano, Buenos Aires, Argentina, ¹²Rheumatology, Hospital Italiano, Buenos Aires, Argentina, ¹³HIGA San Martín, La Plata, Argentina, ¹⁴Rheumatology Unit, HIGA San Martín, La Plata, Argentina, ¹⁵Rheumatology, HIGA San Martín, La Plata, Argentina, ¹⁶Rheumatology, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, ¹⁷Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ¹⁸Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Argentina, ²⁰Centro Integral De Reumatologia, Tucumán, Argentina, ²¹Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, ²²Rheumatology, Hosp. Provincial, Rosario, Argentina, ²³Hosp. Provincial, Rosario, Argentina, ²⁴Hospital Provincial del Centenario, Santa Fe, Argentina
Background/Purpose: Several trials had reported the efficacy and toxicity of methotrexate monotherapy in patients with early rheumatoid arthritis. However, patients outside clinical trials could be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.